Key facts
- This page summarizes Faheem Hasnain's Form 3 filing for Aspen Neuroscience, Inc..
- 0 reported transactions and 5 derivative rows are listed below.
- Accepted by SEC: 29 Oct 2026, 20:14.
Faheem Hasnain - 29 Oct 2026 Form 3 Insider Report for Aspen Neuroscience, Inc.
- Reporting relationship
- Executive Chair, Director
- Issuer ticker
- N/A
- Reported as of
- 29 Oct 2026
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 29 Oct 2026, 20:14:23 UTC
- Prior SEC filing
- 26 Aug 2026
- Source filing
- View source filing
- Reporting owner signature
- By: /s/ Jeffrey L. Boerneke, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Faheem Hasnain filed Form 3 for Aspen Neuroscience, Inc. on 29 Oct 2026.
Change
- Previous filing in this sequence was filed on 26 Aug 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0001352620
Primary reporting owner
Hasnain Faheem
- Relationship
- Executive Chair, Director
- Address
- 10835 ROAD TO THE CURE, SUITE 100, SAN DIEGO
- Signature
- By: /s/ Jeffrey L. Boerneke, as Attorney-in-Fact
- Signature date
- 29 Oct 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
No ticker
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 26,658
- Date
- 29 Oct 2026
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
No ticker
holding
Derivative
Series A-1 Convertible Preferred Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 29 Oct 2026
- Ownership
- See Footnote 2.
- Underlying class
- Common Stock
- Underlying amount
- 14,913
- Exercise price
- Footnotes
- F1, F2
No ticker
holding
Derivative
Series A-2 Convertible Preferred Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 29 Oct 2026
- Ownership
- See Footnote 2.
- Underlying class
- Common Stock
- Underlying amount
- 14,316
- Exercise price
- Footnotes
- F1, F2
No ticker
holding
Derivative
Series C Convertible Preferred Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 29 Oct 2026
- Ownership
- See Footnote 2.
- Underlying class
- Common Stock
- Underlying amount
- 7,120
- Exercise price
- Footnotes
- F1, F2
No ticker
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 29 Oct 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 27,322
- Exercise price
- $7.71
- Footnotes
- F3
No ticker
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 29 Oct 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 41,489
- Exercise price
- $5.74
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Pursuant to the Issuer's Amended and Restated Certificate of Incorporation, as amended, each share of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") may be converted, at the option of the holder, at any time. In connection with the completion of the Issuer's initial public offering of its Common Stock, each share of Preferred Stock will automatically convert on a 1-for-9.8821 basis into shares of Common Stock, for no additional consideration. Share numbers give effect to such conversion. The securities have no expiration date.
Footnote F2
Securities held by the Hasnain Revocable Trust.
Footnote F3
The option was granted on June 16, 2022. The option is fully vested and exercisable.
Footnote F4
The option was granted on November 26, 2025. The shares subject to the option were previously eligible to vest in 48 equal monthly installments beginning on December 20, 2025. In September 2026, the vesting schedule was amended such that the unvested shares subject to the option as of September 25, 2026, shall vest in equal monthly installments through November 20, 2031, subject to the Reporting Person's continuous service through each vesting date.
SEC remarks
Exhibit 24 - Power of Attorney